| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/17/2013 | EP2580208A1 Cyclohexyl-azetidinyl antagonists of ccr2 |
| 04/17/2013 | EP2580207A1 Nitrogen containing heteroaryl compounds |
| 04/17/2013 | EP2580206A2 Pharmaceutical composition comprising amide derivative or pharmaceutically acceptable salt thereof |
| 04/17/2013 | EP2580205A1 Crystalline forms of thalidomide and processes for their preparation |
| 04/17/2013 | EP2580204A1 Cysteamine derivatives and their use in the treatment of nash |
| 04/17/2013 | EP2580200A1 5,6-dihydro-2h-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (bace) |
| 04/17/2013 | EP2580197A1 Anti-inflammatory agents |
| 04/17/2013 | EP2580196A1 Anti-inflammatory agents |
| 04/17/2013 | EP2580195A1 Crystal form of glycopyrronium chloride |
| 04/17/2013 | EP2580194A1 Process for the preparation of glycopyrronium chloride |
| 04/17/2013 | EP2580193A1 Benzamide derivatives and their use as hsp90 inhibtors |
| 04/17/2013 | EP2580191A2 Thioether prodrug compositions as anti-hiv and anti-retroviral agents |
| 04/17/2013 | EP2580190A1 New antiviral compounds |
| 04/17/2013 | EP2580189A1 Agomelatine intermediates and preparation method thereof |
| 04/17/2013 | EP2579896A1 Hydroxypropyl methyl cellulose acetate succinate with enhanced acetate and succinate substitution |
| 04/17/2013 | EP2579888A2 Novel glp-1 receptor stabilizers and modulators |
| 04/17/2013 | EP2579886A1 Phenolic compositions derived from apple skin and uses thereof |
| 04/17/2013 | EP2579880A1 Treatment of type 2 diabetes |
| 04/17/2013 | EP2579879A1 Treatment of type 1 diabetes |
| 04/17/2013 | EP2579878A1 Methods of treating hematological disorders with quinazolinone compounds in selected patients |
| 04/17/2013 | EP2579877A1 Morpholino pyrimidines and their use in therapy |
| 04/17/2013 | EP2579876A2 Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes |
| 04/17/2013 | EP2579875A2 Compositions comprising buprenorphine |
| 04/17/2013 | EP2579874A2 Injectable flowable composition comprising buprenorphine |
| 04/17/2013 | EP2579873A1 Novel prolylcarboxypeptidase inhibitors |
| 04/17/2013 | EP2579872A1 Inhibitors of akt activity |
| 04/17/2013 | EP2579871A1 Topical antiviral formulations for prevention of transmission of hsv-2 |
| 04/17/2013 | EP2579870A2 Trkb agonists and methods of use |
| 04/17/2013 | EP2579869A2 Formulations including amiodarone and salts thereof and methods of their manufacture and use |
| 04/17/2013 | EP2579868A2 Oral iron deficiency therapy |
| 04/17/2013 | EP2579867A1 Triheptanoin diet for adult polyglucosan body disease (apbd) treatment |
| 04/17/2013 | EP2579866A2 Intravaginal administration of misoprostol |
| 04/17/2013 | EP2579865A2 Combination therapy with lisdexamphetamine and extended release guanfacine |
| 04/17/2013 | EP2579864A1 Coordination complexes, pharmaceutical solutions comprising coordination complexes, and methods of treating patients |
| 04/17/2013 | EP2579863A2 Compounds for treatment of bovine mastitis |
| 04/17/2013 | EP2579862A1 Pharmaceutical composition with olive extract (hydroxytyrosol) and hop extract (xanthohumol) for intranasal application |
| 04/17/2013 | EP2579861A2 Transglutaminase 2 inhibitors for use in the prevention or treatment of rapidly progressive glomerulonephritis |
| 04/17/2013 | EP2579860A2 Ivabradine-containing pharmaceutical composition with modified release |
| 04/17/2013 | EP2579859A2 Solid ivabradine-containing composition |
| 04/17/2013 | EP2579858A2 Ivabradine-containing pharmaceutical composition |
| 04/17/2013 | EP2579857A1 Alcohol-resistant extended release dosage forms comprising venlafaxine |
| 04/17/2013 | EP2579856A1 An injectable dosage form of flupirtine |
| 04/17/2013 | EP2579855A2 Solid dispersions containing kinase inhibitors |
| 04/17/2013 | EP2579854A1 Solid compositions |
| 04/17/2013 | EP2579848A2 Process for the preparation of o/w emulsions |
| 04/17/2013 | EP2579847A1 Antimycotic pharmaceutical composition |
| 04/17/2013 | EP2579717A2 Positive allosteric modulators of mglur2 |
| 04/17/2013 | EP2579716A1 Novel prolylcarboxypeptidase inhibitors |
| 04/17/2013 | EP2579715A1 Applications of partially and fully sulfated hyaluronan |
| 04/17/2013 | EP2494956A9 Paclitaxel/steroidal complex |
| 04/17/2013 | EP2014304B9 Colon cleansing compositions |
| 04/17/2013 | EP1841418B1 Glycine reuptake inhibitors for treating drug and alcohol dependence |
| 04/17/2013 | CN1678327B Use of hesperidin or one of its derivatives for making a medicine for bone formation stimulation |
| 04/17/2013 | CN103052719A Prediction of hcv viral kinetics in interferon-free treatment |
| 04/17/2013 | CN103052642A Crystal of tricyclic pyrazolopyrimidine derivative |
| 04/17/2013 | CN103052641A Novel fused heterocyclic derivatives useful as C-Met tyrosine kinase inhibitors |
| 04/17/2013 | CN103052640A Furopyridine derivatives |
| 04/17/2013 | CN103052639A 6-cycloalkyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors |
| 04/17/2013 | CN103052636A D2 antagonists, methods of synthesis and methods of use |
| 04/17/2013 | CN103052634A Theanine derivative, preparation method thereof, and use thereof for alleviating acne |
| 04/17/2013 | CN103052633A Amids Substituted Indazole Derivativees As Ploy(adp-ribose)polymerase Inhibitors |
| 04/17/2013 | CN103052630A Highly crystalline valsartan |
| 04/17/2013 | CN103052627A Pyrimidine derivatives as fak inhibitors |
| 04/17/2013 | CN103052626A 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride amorphous solid forms |
| 04/17/2013 | CN103052619A Methods for treating neurodegenerative diseases |
| 04/17/2013 | CN103052405A Oligonucleotide Chelate Complexes |
| 04/17/2013 | CN103052404A Neuropilin as a biomarker for bevacizumab combination therapies |
| 04/17/2013 | CN103052392A Treatment of lung infections by administration of tobramycin by aerolisation |
| 04/17/2013 | CN103052391A Pyrroloquinoline quinone gel |
| 04/17/2013 | CN103052390A Therapeutic combination comprising parp-1 inhibitor and anti-neoplastic agent |
| 04/17/2013 | CN103052389A Oral medicinal composition for patients undergoing peritoneal dialysis and method for using same |
| 04/17/2013 | CN103052388A Use of sigma ligands in opioid-induced hyperalgesia |
| 04/17/2013 | CN103052387A Pharmaceutical composition containing a tryptophan derivative |
| 04/17/2013 | CN103052386A Composition containing tetracyclic compound |
| 04/17/2013 | CN103052385A Methods of treatment of hepatocellular carcinoma |
| 04/17/2013 | CN103052384A Aqueous composition comprising bromhexine |
| 04/17/2013 | CN103052382A Solid dispersion of alfa-ketoamide derivatives |
| 04/17/2013 | CN103052379A Dry powder formulation comprising a phosphodiesterase inhibitor |
| 04/17/2013 | CN103052378A Pharmaceutical formulation comprising phosphodiesterase inhibitor |
| 04/17/2013 | CN103049662A Application method of response surface analysis to Chinese herbal compound studies |
| 04/17/2013 | CN103045715A Medicament target for treating acute promyelocytic leukemia and inhibitor thereof |
| 04/17/2013 | CN103045674A Preparation method and application of flavone-C-glycoside 6'' hydroxyl-ester derivative |
| 04/17/2013 | CN103045601A Improved modulators of coagulation factors |
| 04/17/2013 | CN103044523A Dexamethasone-RGD polypeptide conjugate, preparation method thereof and application |
| 04/17/2013 | CN103044521A Aspartase-targeted activated adriamycin derivative as well as preparation method and application thereof |
| 04/17/2013 | CN103044518A 3-oxo-7-oximido-4-aza-A-homo-chenodeoxycholic acid methyl ester and 3-O-benzyl oximido-7-aza-7a-oxo-B-homo-chenodeoxycholic acid methyl ester, and application of 3-oxo-7-oximido-4-aza-A-homo-chenodeoxycholic acid methyl ester and 3-O-benzyl oximido-7-aza-7a-oxo-B-homo-chenodeoxycholic acid methyl ester in preparing antineoplastic drug |
| 04/17/2013 | CN103044514A Preparation method of 3beta-hydroxy-6-thiosemicarbazone steroid metal complex and application of metal complex in antineoplastic drug |
| 04/17/2013 | CN103044509A Gamma-cytidine-5'-disodium triphosphate crystal compound, and preparation method and drug composition of crystal compound |
| 04/17/2013 | CN103044500A Preparation for organic acid and application for antibacterium |
| 04/17/2013 | CN103044483A Triphenyltin (IV) coordination compound and preparation method and application thereof |
| 04/17/2013 | CN103044477A Trimethyl silicon substituted benzopyran compound and application thereof |
| 04/17/2013 | CN103044460A 3,5,7-triphenyl-5H-thiazolo[3,2-a]pyrimidin derivatives and application thereof |
| 04/17/2013 | CN103044459A Novel cefmetazole compound and medicine composition thereof |
| 04/17/2013 | CN103044453A Cefamandole nafate compound and pharmaceutical composition thereof |
| 04/17/2013 | CN103044450A Ceftizoxime sodium compound and preparation method and drug composition of ceftizoxime sodium compound |
| 04/17/2013 | CN103044449A Novel ceftizoxime sodium compound and medicine composition thereof |
| 04/17/2013 | CN103044446A Heterocycle quinoline derivatives as well as medicinal salts, preparation method and medicinal application thereof |
| 04/17/2013 | CN103044439A De-malonate monoacyl azalomycin F, preparation method thereof and application thereof to preparation of MRSA infection therapeutic drug |
| 04/17/2013 | CN103044432A 双环杂芳基化合物 Bicyclic heteroaryl compounds |
| 04/17/2013 | CN103044426A Ganciclovir crystal compound, new composition thereof and preparation method thereof |